Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fulvestrant

FDA-approved product (solution, intramuscular), marketed as Cligavyx, Faslodex, Fulvestrant.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Fulvestrant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • HER2 Positive Breast Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-estrogens
FDA pharmacologic class
Estrogen Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fulvestrant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fulvestrant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

    NCT03227328 · start 2017-08-02

    Registered record
    Registry ID
    NCT03227328
    Conditions
    Hormone Receptor Positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Negative Breast Cancer
    Interventions
    concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy; chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-08-02
    Completion
    2022-07-01
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHormone Receptor Positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Negative Breast Cancer
    Interventionconcomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy; chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
    PhasePhase 2
    Registry statusCompleted

  • Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy

    NCT03220178 · start 2017-07-24

    Registered record
    Registry ID
    NCT03220178
    Conditions
    Breast Neoplasm
    Interventions
    Palbociclib; Fulvestrant; Anastrozole; Letrozole; Exemestane
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-07-24
    Completion
    2021-12-07
    Enrolment
    532

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasm
    InterventionPalbociclib; Fulvestrant; Anastrozole; Letrozole +1 more
    PhasePhase 4
    Registry statusTerminated

  • GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

    NCT02983604 · start 2017-01-10

    Registered record
    Registry ID
    NCT02983604
    Conditions
    Advanced Estrogen Receptor Positive HER2- Breast Cancer
    Interventions
    GS-5829; Exemestane; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2017-01-10
    Completion
    2018-07-19
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Estrogen Receptor Positive HER2- Breast Cancer
    InterventionGS-5829; Exemestane; Fulvestrant
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

    NCT02763566 · start 2016-12-05

    Registered record
    Registry ID
    NCT02763566
    Conditions
    Breast Cancer
    Interventions
    Abemaciclib; Anastrozole; Letrozole; Placebo; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2016-12-05
    Completion
    2028-03
    Enrolment
    463

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAbemaciclib; Anastrozole; Letrozole; Placebo +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

    NCT04524728 · start 2016-12

    Registered record
    Registry ID
    NCT04524728
    Conditions
    Breast; Neoplasm Malignant; Female
    Interventions
    Palbociclib; Letrozole 2.5mg; Fulvestrant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-12
    Completion
    2020-06
    Enrolment
    191

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast; Neoplasm Malignant; Female
    InterventionPalbociclib; Letrozole 2.5mg; Fulvestrant
    PhaseNot recorded
    Registry statusCompleted

  • Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

    NCT02630693 · start 2016-04-08

    Registered record
    Registry ID
    NCT02630693
    Conditions
    Breast Cancer
    Interventions
    Palbociclib 100mg; Palbociclib 125mg; Fulvestrant or Tamoxifen or Aromatase Inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-04-08
    Completion
    2023-11-29
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionPalbociclib 100mg; Palbociclib 125mg; Fulvestrant or Tamoxifen or Aromatase Inhibitor
    PhasePhase 2
    Registry statusCompleted

  • Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase

    NCT02640755 · start 2016-01-28

    Registered record
    Registry ID
    NCT02640755
    Conditions
    Solid Malignancies
    Interventions
    [14C]AZD2014; Multiple dose AZD2014; Fulvestrant; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-01-28
    Completion
    2017-07-06
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Malignancies
    Intervention[14C]AZD2014; Multiple dose AZD2014; Fulvestrant; Paclitaxel
    PhasePhase 1
    Registry statusCompleted

  • A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer

    NCT02216786 · start 2014-01-16

    Registered record
    Registry ID
    NCT02216786
    Conditions
    Estrogen Receptor Positive Breast Cancer
    Interventions
    AZD2014; Everolimus; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-01-16
    Completion
    2021-12-31
    Enrolment
    333

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstrogen Receptor Positive Breast Cancer
    InterventionAZD2014; Everolimus; Fulvestrant
    PhasePhase 2
    Registry statusCompleted

  • Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

    NCT01942135 · start 2013-09-26

    Registered record
    Registry ID
    NCT01942135
    Conditions
    Metastatic Breast Cancer
    Interventions
    Palbociclib; Fulvestrant; Placebo; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09-26
    Completion
    2022-09-28
    Enrolment
    521

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionPalbociclib; Fulvestrant; Placebo; Fulvestrant
    PhasePhase 3
    Registry statusCompleted

  • Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer

    NCT01399086 · start 2011-04

    Registered record
    Registry ID
    NCT01399086
    Conditions
    Breast Cancer
    Interventions
    Fulvestrant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-04
    Completion
    2011-09
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionFulvestrant
    PhaseNot recorded
    Registry statusCompleted

  • A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

    NCT00728949 · start 2008-08

    Registered record
    Registry ID
    NCT00728949
    Conditions
    Metastatic Breast Cancer
    Interventions
    IMC-A12 (cixutumumab); tamoxifen; Anastrozole; Letrozole; Exemestane; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-08
    Completion
    2015-02
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionIMC-A12 (cixutumumab); tamoxifen; Anastrozole; Letrozole +2 more
    PhasePhase 2
    Registry statusCompleted

  • AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

    NCT00454805 · start 2007-03

    Registered record
    Registry ID
    NCT00454805
    Conditions
    Advanced Breast Cancer
    Interventions
    AZD2171; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-03
    Completion
    2016-04
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    InterventionAZD2171; Fulvestrant
    PhasePhase 2
    Registry statusCompleted

  • Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

    NCT00372996 · start 2007-02

    Registered record
    Registry ID
    NCT00372996
    Conditions
    Breast Neoplasms
    Interventions
    CP-751,871; exemestane; exemestane; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-02
    Completion
    2014-06
    Enrolment
    219

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms
    InterventionCP-751,871; exemestane; exemestane; Fulvestrant
    PhasePhase 2
    Registry statusTerminated

  • A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg

    NCT00305448 · start 2006-03

    Registered record
    Registry ID
    NCT00305448
    Conditions
    Advanced Breast Cancer; Metastatic Breast Cancer
    Interventions
    Fulvestrant; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-03
    Completion
    2012-02
    Enrolment
    143

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer; Metastatic Breast Cancer
    InterventionFulvestrant; Fulvestrant
    PhasePhase 2
    Registry statusCompleted

  • Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

    NCT00099437 · start 2005-02-13

    Registered record
    Registry ID
    NCT00099437
    Conditions
    Breast Cancer
    Interventions
    Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2005-02-13
    Completion
    2026-12-31
    Enrolment
    736

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionFulvestrant
    PhasePhase 3
    Registry statusActive not recruiting